How to price a bio/pharmaceutical drug is one of the most complex topics for pharmaceutical executives, as there are many factors to consider. Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, reveals the following to Pharmaceutical Executive® in this exclusive Pharm Exec Podcast interview: 1) the biggest drug pricing challenges today; 2) current efforts to lower drug pricing; 3) what companies should consider as it relates to drug pricing from a legal perspective; 3) the status of the Inflation Reduction Act (IRA), specifically what should companies be watching for; 4) potential impact on companies from the IRA; 5) IRA milestones we will be seeing through the end of the year; and 6) drug pricing recommendations (from a legal perspective).

ACT podcast: https://www.appliedclinicaltrialsonline.com/editorial-podcasts

In this podcast, Sharlene Jenner, vice president of engagement strategy at Abelson Taylor and professor of AI and personalization for digital marketers at Southern Methodist University, leads a panel of five industry leaders in a roundtable discussion. The conversation delves into the practicalities of current AI applications and confronts the ethical and regulatory issues related to the technology. The panelists also explore the direct consequences and prospective implications of AI, providing listeners with a snapshot of the present and an outlook on the transformative potential of emerging technologies in the pharmaceutical marketing sphere.

The panel consists of: Faruk Capan, chief innovation officer, EVERSANA, and CEO, EVERSANA INTOUCH; Anurag Banerjee, CEO and founder, Quilt.AI; Jeff Headd, vice president, commercial data science, The Janssen Pharmaceutical Companies of Johnson & Johnson; and Stephen Onikoro, senior principal, head of strategy, PharmaForceIQ.

Sponsored by: ZS https://www.zs.com/

In this podcast, Mohit Manrao, the SVP and head of US oncology at AstraZeneca, shares his journey from growing up in Northern India with aspirations of becoming a doctor, to leading oncology initiatives at AstraZeneca in the US. A central strategy to ultimately eliminate cancer includes ensuring that the latest scientific advancements are accessible to patients in every zip code and the necessity of integrating the patient perspective at every stage—from early discovery to commercialization, recognizing the importance of diverse patient needs, non-invasive diagnostics, and alleviating challenges in access to screenings and treatments.

Welcome to a riveting episode of the Pharm Exec podcast, where we dive headfirst into the transformative world of AI in healthcare with Sharlene Jenner, vice president of engagement strategy with the award-winning agency Abelson Taylor. This enlightening conversation traverses the advancements and potential risks of AI, the revolution it is stirring in pharmaceutical marketing, and its game-changing role in understanding complex protein structures. Amid the rapid innovation, we explore the urgent need for ethical guidelines and regulations to keep pace with technology.

We all know that the pharma industry is about people—bettering the lives of others through good research, life-changing pharmaceuticals, and keeping the patient front and center. But Jag Dosanjh, president, US neuroscience and eye care, AbbVie, lives that principle. In this podcast episode, Meg Rivers, managing editor, talks with Dosanjh about what he calls a “people business” and his approach to leadership. He starts his career in the medical sales space before working in many different roles and therapeutic areas before ultimately landing at AbbVie. He was also nominated HBA’s mentor of the year and shares insights into being a good leader and mentor. One of his tips was: “If you listen well, you can learn well.” In addition, he emphasized the importance of curiosity, learning, and the pursuit of a smile.

This Pharma 50 companion episode delves into the vital topic of trust within the pharmaceutical industry. Morton Nielsen, senior partner for the life sciences practice at Wittkieffer, dissects the concept, drawing on parallels to Maslow's hierarchy of needs, and discusses practical methods for measuring and operationally improving trust. This episode is a must-listen for those interested in understanding the current state and future evolution of trust in the pharmaceutical sector, an industry where trust forms a fundamental pillar for delivering on its mission statement.

Read the 2023 Pharma 50 article here: https://www.pharmexec.com/view/2023-pharm-exec-top-50-companies

The 2023 Emerging Pharma Leaders share with Meg Rivers, managing editor of Pharmaceutical Executive, and the editorial team what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more.

Congratulations to the 2023 Emerging Pharma Leaders: Natasha A. Hernday, chief business officer, Seagen; Simon Holland, vice president, women's health commercial lead, Organon; Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio; Frank Watanabe, president and CEO, Arcutis Biotherapeutics; and Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics.

SPONSOR: APEX Awards

https://www.pharmexec.com/apex-awards

Launching a drug and receiving approvals—whether it’s in the U.S. or globally—is challenging to navigate. It’s a process that often takes years and a lot of back-and-forth communication with regulatory bodies.

In this episode, Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, discusses drug approvals and drug launches from a legal perspective, including 1) his work as an attorney; 2) tips for drug approvals from a legal perspective; 3) current regulatory challenges the industry is facing in the U.S.; 4) the shift away from a one-sized-fits all approach to marketing and global launches; 5) tips for companies navigating the regulatory landscape in the U.S.; 6) when to launch a drug in a country outside of the U.S.; and 7) drug pricing. Join Meg Rivers, managing editor, as she dives into this topic with Cope.

In this episode of the Pharmaceutical Executive Podcast, we dive into a conversation with Frank Watanabe, president and CEO of Arcutis, a medical dermatology company with a patient-first approach. Discover how Arcutis is transforming the dermatology landscape with its innovative product offerings, such as FDA-approved Zoryve for topical treatment of plaque psoriasis and their upcoming products for seborrheic dermatitis and atopic dermatitis. Learn about the company's guiding principles, the importance of keeping patients at the forefront of decision-making, and the need for further innovation in the dermatology sector after decades of stagnation.

Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, speaks with Meg Rivers, managing editor, about: 1) her journey into the world of pharma, including her transition from being a physician/surgeon to working in clinical trials; 2) both women’s and men’s reproductive health; 3) the latest technologies in fertility treatment (for men and women); 4) unmet needs in fertility care; 5) trends in contraception and fertility treatment; 6) DE&I and access to care, and 7) predictions for the contraception and fertility treatment spaces in the coming years